| ASSEMBLY BIOSCIENCES INC |
| USA |
| Gesundheit |
| US0453962070 / A402CB |
| V7B (Frankfurt) / ASMB (NASDAQ) |
| FRA:V7B, ETR:V7B, V7B:GR, NASDAQ:ASMB |
| - |
| https://www.assemblybio.c.. |
|
Assembly Biosciences Inc. is a biopharmaceutical company that focuses on the discovery and development of innovative therapeutics targeting chronic hepatitis B virus (HBV) infection and other viral di..
>Volltext.. |
| 375.96 Mio. EUR |
| 182.1 Mio. EUR |
| 32.12 Mio. EUR |
| -37.42 Mio. EUR |
| -33.29 Mio. EUR |
| -4.15 EUR |
| 2.38 Mio. EUR |
| 19.46 Mio. EUR |
| -48.14 Mio. EUR |
| 4.36 |
| 24.58% |
| 10.36% |
| - |
| - |
| - |
| - |
| ASSEMBLY BIOSCIENCES, ASSEMBLY BIO, ASSEMBLY BIOSCIENCE |
| 20.03.26 |
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|